New Product Launches and Approvals
The pharmaceutical and food industries are constantly developing at a significant rate due to the rising demand from a large population has increased new product development, product launches, and approvals on a regional level. Additionally, major market players are involved in research and development activities to ensure the innovation and development of efficient products. In recent years there have been various developments, such as product launches and approvals taking place in the market, which are likely to create ample opportunities in the market. For instance, In July 2021, Ligand Pharmaceuticals Incorporated partnered with Jazz Pharmaceuticals Plc to launch Rylaze (asparaginase Erwinia Chrysanthemi (recombinant)-rywn), also known as JZP458. Rylaze is a recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for treating acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. Similarly, in August 2020, Lonza expanded microbial capacity and extended long-term partnership with Servier Pharmaceuticals, Inc. for l-asparaginase API manufacturing. The new facility will provide mid-scale commercial manufacturing to multiple customers and serve the growing needs of Servier, an independent international pharmaceutical company and long-term Lonza partner. Thus, the increase in new product development, launches, and other strategic collaborations among market players are likely to create ample opportunities and drive market growth in the coming years.
Market Overview
The SAM asparaginase market is segmented into Brazil, Argentina, and the Rest of SAM. Brazil dominated the market in 2022. As per World Health Organization report, 11,445 new cases of non-Hodgkin lymphoma and 11,363 new cases of leukemia were reported in Brazil in 2020. There has been development in healthcare facilities and products along with the rising prevalence of leukemia and lymphoma in Brazil. According to National Library of Medicine report, the Brazilian Ministry of Health acquired a new l-asparaginase produced by Beijing SL Pharmaceutical (China) with the trade name of Leuginase in 2017. Moreover, Brazil has the second largest food processing industry in North America and South America, after the US. The country also has the second largest agricultural industry and also exports most of the food items and ingredients to the neighboring countries. Brazil has experienced significant growth in the food process industry, which has further created the demand for asparaginase. For instance, according to Brazilian Food Processors' Association, the Brazil food processing industry generated the revenue of US$ 171 billion in 2021, which is an increase of 16.9% as compared to 2020. Thus, the rising prevalence of leukemia and lymphoma, along with surge in application of asparaginase in the agricultural & food industries in the country, is expected to proliferate the growth of asparaginase market over the forecast period.
SAM Asparaginase Market Segmentation
The SAM asparaginase market is segmented based on type, application, end-use industry, and country.
Based on type, the SAM asparaginase market is segmented into escherichia coli, erwinia chrysanthemi, pegylated, and others. The escherichia coli segment held the largest market share in 2022. Based on application, the SAM asparaginase market is segmented into therapeutic, food processing, and others. The therapeutic segment held the largest market share in 2022. The therapeutic segment is further classified into acute lymphoblastic leukemia, lymphoblastic lymphoma, and others. Based on end-use industry, the SAM asparaginase market is bifurcated into healthcare and food manufacturing. The healthcare segment held the larger market share in 2022. Based on country, the SAM asparaginase market has been categorized into Brazil, Argentina, and rest of SAM. Our regional analysis states that Brazil dominated the market in 2022. Biovendor, LLC; Creative Enzymes; Jazz Pharmaceuticals, Inc.; medac GMBH; Servier Pharmaceuticals LLC; Taj Pharmaceuticals Limited; and United Biotech (P) Limited are the leading companies operating in the SAM asparaginase market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 32.29 Million |
| Market Size by 2028 | US$ 73.24 Million |
| CAGR (2022 - 2028) | 14.6% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered |
South and Central America
|
| Market leaders and key company profiles |
|
The South America Asparaginase Market is valued at US$ 32.29 Million in 2022, it is projected to reach US$ 73.24 Million by 2028.
As per our report South America Asparaginase Market, the market size is valued at US$ 32.29 Million in 2022, projecting it to reach US$ 73.24 Million by 2028. This translates to a CAGR of approximately 14.6% during the forecast period.
The South America Asparaginase Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South America Asparaginase Market report:
The South America Asparaginase Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South America Asparaginase Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South America Asparaginase Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South America Asparaginase Market
